معرفی
Liling Wan is an Assistant Professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania, and an Assistant Investigator at the Abramson Family Cancer Research Institute. Her lab investigates the intersection of cancer biology and epigenetics, focusing on chromatin regulation in cellular fate transitions and cancer progression.
- Affiliated with Penn Epigenetics Institute
- Member of Abramson Family Cancer Research Institute
- Part of Institute for Regenerative Medicine
- Graduate group affiliations in Biochemistry, Pharmacology, and Cell/Molecular Biology
Wan's research explores chromatin's role in cancer through mechanisms involving histone modifications, transcriptional condensates, and cell fate plasticity. Her work on ENL mutations in leukemia and MTDH-SND1 interactions in breast cancer has significant implications for cancer therapy development.
Recent publications highlight her focus on transcriptional condensates in cancer pathogenesis, with 2024 studies examining ENL mutation effects in kidney development and AML progression. Her therapeutic work includes developing YEATS domain inhibitors and demonstrating RNA's role in oncogenic condensates.
- 2025 Pershing Square Sohn Cancer Prize recipient
- 2025 Tony Hunter Junior Investigator Award winner
- Co-inventor of cancer treatment peptides (US Patent 10,357,539 B2)
Her lab employs multidisciplinary approaches including mouse models, genome-wide sequencing, advanced imaging, and biochemistry. Current research directions include decoding chromatin-associated condensate regulation and characterizing novel epigenetic cancer therapies.
